CLINICAL_TRIALS
trial_result
· 2012-07-04
Clinical Trial Update: Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) [Phase 1]
Summary
Phase I study of vorinostat (MK-0683) in cutaneous T-cell lymphoma (CTCL) completed; results posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2012-07-04